Candel Therapeutics, Inc. (CADL) shareholders
Close on Nov 18, 2026Market cap $407.08MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Roderick Wong Joint filing with RTW Investments, LP (8.80%) | 6,422,018 | 8.80% | 13G (passive) | Mar 31, 2026 |
| Paul B Manning | 5,790,999 | 7.90% | 13D (active) amendment | Dec 16, 2024 |
| BlackRock, Inc. | 4,834,899 | 6.60% | 13G (passive) | Jun 30, 2026 |
| FMR LLC Joint filing with Abigail P. Johnson (9.30%) | 3,923,599 | 9.30% | 13G (passive) | Dec 31, 2024 |
| Anders Hove | 2,580,517 | 5.20% | 13G (passive) | Jun 25, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CADL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 10,990,535 | 14.36% | $113.20M | +3,518 | 0.00% |
| Rtw Investments, LP | 6,422,018 | 8.39% | $66.15M | – | 0.56% |
| BlackRock, Inc. | 4,969,040 | 6.49% | $51.18M | +1,859,998 | 0.00% |
| State Street Corp | 3,549,823 | 4.64% | $36.56M | +2,731,265 | 0.00% |
| Acorn Capital Advisors, LLC | 3,497,948 | 4.57% | $36.03M | – | 9.83% |
| Portolan Capital Management, LLC | 3,490,398 | 4.56% | $35.95M | +596,073 | 1.35% |
| Saturn V Capital Management LP | 3,303,686 | 4.32% | $34.03M | +407,098 | 4.88% |
| Vanguard Capital Management LLC | 2,694,040 | 3.52% | $27.75M | +231,283 | 0.00% |
| Geode Capital Management, LLC | 1,571,021 | 2.05% | $16.18M | +535,586 | 0.00% |
| Millennium Management LLC | 1,093,905 | 1.43% | $11.27M | +33,819 | 0.00% |
| Halter Ferguson Financial Inc. | 772,461 | 1.01% | $7.96M | −131,590 | 1.29% |
| Northern Trust Corp | 492,465 | 0.64% | $5.07M | +169,311 | 0.00% |
| Kennedy Capital Management LLC | 488,291 | 0.64% | $5.03M | +395,666 | 0.09% |
| Vanguard Portfolio Management LLC | 437,150 | 0.57% | $4.50M | +168,901 | 0.00% |
| Vanguard Fiduciary Trust Co | 412,109 | 0.54% | $4.24M | +131,658 | 0.00% |
| Sands Capital Ventures, LLC | 405,837 | 0.53% | $4.18M | – | 0.68% |
| Goldman Sachs Group Inc | 305,216 | 0.40% | $3.14M | +77,695 | 0.00% |
| Marshall Wace, Llp | 300,641 | 0.39% | $3.10M | New | 0.00% |
| Bank Of America Corp /De/ | 278,944 | 0.36% | $2.87M | +231,542 | 0.00% |
| Susquehanna International Group, Llp | 227,939 | 0.30% | $2.35M | +114,966 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 138 | 50M | 65.9% | 40 / 63 | 24 / 13 | 10M | 3M |
| Q1 2026 | 114 | 43M | 56.8% | 39 / 40 | 22 / 8 | 23M | 1M |
| Q4 2025 | 84 | 24M | 30.9% | 13 / 32 | 19 / 10 | 2M | 1M |
| Q3 2025 | 81 | 23M | 29.6% | 15 / 27 | 23 / 12 | 1M | 2M |
| Q2 2025 | 78 | 23M | 30.1% | 16 / 40 | 14 / 20 | 5M | 3M |
| Q1 2025 | 82 | 21M | 27.7% | 24 / 39 | 12 / 12 | 6M | 3M |
| Q4 2024 | 71 | 18M | 23.5% | 22 / 32 | 10 / 2 | 13M | 0M |
| Q3 2024 | 52 | 7M | 8.8% | 16 / 16 | 10 / 8 | 2M | 1M |
| Q2 2024 | 45 | 6M | 7.8% | 31 / 9 | 4 / 6 | 3M | 1M |
| Q1 2024 | 20 | 4M | 4.9% | 4 / 6 | 5 / 5 | 0M | 0M |
| Q4 2023 | 22 | 4M | 5.3% | 4 / 5 | 6 / 2 | 0M | 1M |
| Q3 2023 | 20 | 5M | 6.9% | 2 / 5 | 5 / 2 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
114 funds held CADL in Q2 2026, 41% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CADL | Value | % of fund | As of |
|---|---|---|---|---|---|
| Select Biotechnology Portfolio | 4,864,753 | 6.36% | $40.38M | 0.77% | May 31, 2026 |
| Fidelity Growth Company Fund | 2,111,072 | 2.76% | $17.52M | 0.02% | May 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,024,039 | 2.65% | $20.85M | 0.19% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,968,034 | 2.57% | $20.27M | 0.00% | Jun 30, 2026 |
| Strategic Advisers U.S. Total Stock Fund | 1,814,352 | 2.37% | $15.06M | 0.02% | May 31, 2026 |
| iShares Russell 2000 ETF | 1,650,828 | 2.16% | $17.00M | 0.02% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 693,034 | 0.91% | $6.94M | 0.02% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 659,084 | 0.86% | $6.79M | 0.01% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 602,103 | 0.79% | $5.00M | 0.02% | May 31, 2026 |
| iShares Russell 2000 Growth ETF | 556,180 | 0.73% | $5.73M | 0.04% | Jun 30, 2026 |
| Fidelity Series Growth Company Fund | 555,760 | 0.73% | $4.61M | 0.02% | May 31, 2026 |
| iShares Biotechnology ETF | 410,502 | 0.54% | $4.23M | 0.05% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF | 264,530 | 0.35% | $2.72M | 0.10% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 233,623 | 0.31% | $1.94M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF | 211,492 | 0.28% | $2.18M | 0.14% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Paul Peter Tak | Chief Executive Officer, Director | 113,321 | 0.15% | Sep 11, 2026 |
| Maria Ostrovsky | General Counsel | – | – | Nov 5, 2026 |
| Seshu Tyagarajan | Chief Technology Officer | 76,865 | 0.10% | Aug 19, 2026 |
| Mark E. Sims | Chief Commercial Officer | – | – | Jul 8, 2026 |
| Francesca Barone | Chief Scientific Officer | 77,362 | 0.10% | Jul 1, 2026 |
| Charles Schoch | Chief Financial Officer | 43,391 | 0.06% | Jan 28, 2026 |
| William Garrett Nichols | Chief Medical Officer | 52,493 | 0.07% | Jan 28, 2026 |
| Paul B. Manning | Director | 5,748,279 | 7.51% | Oct 2, 2026 |
| Nicoletta Loggia | Director | 2,141 | 0.00% | Oct 2, 2026 |
| Joseph C. Papa | Director | 102,271 | 0.13% | Oct 2, 2026 |
| Martine Zimmermann | Director | – | – | Sep 10, 2026 |
| Renee Gaeta | Director | – | – | Jun 24, 2026 |
| Christopher Martell | Director | 698,863 | 0.91% | Jun 24, 2026 |
| Maha Radhakrishnan | Director | – | – | Jun 24, 2026 |
| Gary J. Nabel | Director | 5,353 | 0.01% | Jun 24, 2026 |
| Diem Nguyen | Director | 10,000 | 0.01% | Jun 24, 2026 |
| Edward J. Benz JR | Director | – | – | Jun 24, 2026 |
| Estuardo Aguilar-Cordova | 10% owner | 4,371,832 | 5.71% | Feb 25, 2025 |
| Laura K. Aguilar | 10% owner | 4,574,440 | 5.98% | Feb 25, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Paul Peter Tak Chief Executive Officer, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −59,379 | $10.46 | $621.10K | 113,321 |
| Paul Peter Tak Chief Executive Officer, Director | Sep 10, 2026 | Sale(10b5-1 plan) | −220,866 | $11.50 | $2.54M | 172,700 |
| Paul Peter Tak Chief Executive Officer, Director | Sep 10, 2026 | Option exercise | +125,000 | $1.55 | $193.75K | 393,566 |
| Seshu Tyagarajan Chief Technology Officer | Aug 17, 2026 | Sale(10b5-1 plan) | −7,000 | $12.00 | $84.00K | 76,865 |
| Francesca Barone Chief Scientific Officer | Jun 29, 2026 | Sale(10b5-1 plan) | −23,447 | $10.06 | $235.88K | 77,362 |
| Seshu Tyagarajan Chief Technology Officer | Jun 29, 2026 | Sale(10b5-1 plan) | −7,000 | $10.02 | $70.14K | 83,865 |
| Paul B. Manning Director | Feb 23, 2026 | Buy | +550,458 | $5.45 | $3.00M | 2,763,527 |
| William Garrett Nichols Chief Medical Officer | Jul 28, 2025 | Sale(10b5-1 plan) | −937 | $6.98 | $6.54K | 52,493 |
| William Garrett Nichols Chief Medical Officer | Jul 28, 2025 | Option exercise | +937 | $1.29 | $1.21K | 53,430 |
| William Garrett Nichols Chief Medical Officer | Jun 30, 2025 | Sale(10b5-1 plan) | −781 | $5.04 | $3.94K | 52,493 |
| William Garrett Nichols Chief Medical Officer | Jun 30, 2025 | Option exercise | +781 | $1.29 | $1.01K | 53,274 |
| Seshu Tyagarajan Chief Technology Officer | Jun 25, 2025 | Award | +5,353 | $4.67 | $25.00K | 90,865 |
| Joseph C. Papa Director | Jun 25, 2025 | Award | +64,239 | $4.67 | $300.00K | 64,239 |
| Nicoletta Loggia Director | Jun 25, 2025 | Award | +2,141 | $4.67 | $10.00K | 2,141 |
| Gary J. Nabel Director | Jun 25, 2025 | Award | +5,353 | $4.67 | $25.00K | 5,353 |
| Charles Schoch Chief Financial Officer | Jun 25, 2025 | Award | +5,353 | $4.67 | $25.00K | 43,391 |
| Christopher Martell Director | Jun 25, 2025 | Award | +111,349 | $4.67 | $520.00K | 111,349 |
| Paul Peter Tak Chief Executive Officer, Director | Jun 25, 2025 | Award | +42,826 | $4.67 | $200.00K | 268,566 |
| Paul B. Manning Director | Jun 25, 2025 | Award | +1,070,663 | $4.67 | $5.00M | 2,213,069 |
| Francesca Barone Chief Scientific Officer | Jun 25, 2025 | Award | +4,282 | $4.67 | $20.00K | 100,809 |
| Paul Peter Tak Chief Executive Officer, Director | Mar 19, 2025 | Sale(10b5-1 plan) | −400 | $9.00 | $3.60K | 225,740 |
| William Garrett Nichols Chief Medical Officer | Mar 18, 2025 | Sale(10b5-1 plan) | −45,316 | $8.76 | $396.97K | 52,493 |
| William Garrett Nichols Chief Medical Officer | Mar 18, 2025 | Option exercise | +13,905 | $1.29 | $17.94K | 97,809 |
| William Garrett Nichols Chief Medical Officer | Mar 18, 2025 | Option exercise | +4,584 | $3.75 | $17.19K | 83,904 |
| Paul Peter Tak Chief Executive Officer, Director | Mar 18, 2025 | Sale(10b5-1 plan) | −25,772 | $8.77 | $226.02K | 226,140 |
| Francesca Barone Chief Scientific Officer | Mar 18, 2025 | Sale(10b5-1 plan) | −32,146 | $8.76 | $281.60K | 96,527 |
| Francesca Barone Chief Scientific Officer | Mar 18, 2025 | Option exercise | +18,000 | $1.55 | $27.90K | 128,673 |
| Seshu Tyagarajan Chief Technology Officer | Mar 17, 2025 | Option exercise | +20,000 | $1.29 | $25.80K | 116,790 |
| Seshu Tyagarajan Chief Technology Officer | Mar 17, 2025 | Sale(10b5-1 plan) | −31,278 | $8.82 | $275.87K | 85,512 |
| Charles Schoch See Remarks | Mar 17, 2025 | Sale(10b5-1 plan) | −5,000 | $8.83 | $44.15K | 38,038 |
| Seshu Tyagarajan Chief Technology Officer | Mar 17, 2025 | Sale(10b5-1 plan) | −31,278 | $8.82 | $275.87K | 85,512 |
| Estuardo Aguilar-Cordova 10% owner | Feb 21, 2025 | Returned to company | −10,582 | $12.02 | $127.20K | 120,861 |
| Estuardo Aguilar-Cordova 10% owner | Feb 21, 2025 | Returned to company | −10,583 | $12.02 | $127.21K | 162,929 |
| Estuardo Aguilar-Cordova 10% owner | Feb 10, 2025 | Returned to company | −31,335 | $8.61 | $269.79K | 60,000 |
| Seshu Tyagarajan Chief Technology Officer | Jan 15, 2025 | Sale | −14,322 | $7.23 | $103.55K | 96,790 |
| Paul Peter Tak Chief Executive Officer, Director | Jan 15, 2025 | Sale | −21,704 | $7.23 | $156.92K | 251,912 |
| Francesca Barone Chief Scientific Officer | Jan 15, 2025 | Sale | −13,534 | $7.23 | $97.85K | 110,673 |
| Charles Schoch See Remarks | Jan 15, 2025 | Sale | −9,511 | $7.23 | $68.76K | 43,038 |
| William Garrett Nichols Chief Medical Officer | Jan 15, 2025 | Sale | −10,428 | $7.23 | $75.39K | 79,320 |
| Seshu Tyagarajan Chief Technology Officer | Jan 8, 2025 | Sale | −14,545 | $8.22 | $119.56K | 111,112 |
| Charles Schoch See Remarks | Jan 8, 2025 | Sale | −9,971 | $8.22 | $81.96K | 52,549 |
| William Garrett Nichols Chief Medical Officer | Jan 8, 2025 | Sale | −10,799 | $8.22 | $88.77K | 89,748 |
| Francesca Barone Chief Scientific Officer | Jan 8, 2025 | Sale | −13,673 | $8.22 | $112.39K | 124,207 |
| Paul Peter Tak Chief Executive Officer, Director | Jan 8, 2025 | Sale | −21,172 | $8.22 | $174.03K | 273,616 |
| Laura K. Aguilar 10% owner | Dec 27, 2024 | Returned to company | −50,000 | $8.85 | $442.50K | 131,443 |
| Laura K. Aguilar 10% owner | Dec 27, 2024 | Returned to company | −50,000 | $8.85 | $442.50K | 173,512 |
| Laura K. Aguilar 10% owner | Dec 26, 2024 | Returned to company | −50,000 | $9.01 | $450.50K | 181,443 |
| Laura K. Aguilar 10% owner | Dec 26, 2024 | Returned to company | −50,000 | $9.01 | $450.50K | 223,512 |
| Laura K. Aguilar 10% owner | Dec 24, 2024 | Returned to company | −50,000 | $8.82 | $441.00K | 231,443 |
| Laura K. Aguilar 10% owner | Dec 24, 2024 | Returned to company | +50,000 | $8.82 | $441.00K | 273,512 |
| Laura K. Aguilar 10% owner | Dec 23, 2024 | Returned to company | −50,000 | $8.52 | $426.00K | 281,443 |
| Laura K. Aguilar 10% owner | Dec 23, 2024 | Returned to company | −50,000 | $8.52 | $426.00K | 323,512 |
| Laura K. Aguilar 10% owner | Dec 20, 2024 | Returned to company | −100,000 | $9.00 | $900.00K | 373,512 |
| Laura K. Aguilar 10% owner | Dec 20, 2024 | Returned to company | −100,000 | $9.00 | $900.00K | 331,443 |
| Paul B. Manning Director | Dec 16, 2024 | Buy | +750,000 | $6.00 | $4.50M | 1,303,752 |
| Paul B. Manning Director | Dec 16, 2024 | Buy | +500,000 | $6.00 | $3.00M | 1,142,406 |
| Estuardo Aguilar-Cordova 10% owner | Dec 12, 2024 | Returned to company | −200,000 | $10.04 | $2.01M | 473,512 |
| Estuardo Aguilar-Cordova 10% owner | Dec 12, 2024 | Returned to company | −200,000 | $10.04 | $2.01M | 431,443 |
| Estuardo Aguilar-Cordova 10% owner | Dec 11, 2024 | Returned to company | −200,000 | $8.53 | $1.71M | 631,443 |
| Estuardo Aguilar-Cordova 10% owner | Dec 11, 2024 | Returned to company | −200,000 | $8.53 | $1.71M | 673,512 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Candel Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 117,062 shares on Sep 11, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Paul Peter Tak Director, Officer | Sep 10, 2026 | 280,245 | $3.41M | Sep 10, 2026 | Exercise of Stock Options |
| Seshu Tyagarajan Officer | Aug 17, 2026 | 7,000 | $82.04K | Aug 17, 2026 | Restricted Stock Units |
| Francesca Barone Officer | Jun 29, 2026 | 23,447 | $229.55K | Jun 29, 2026 | Restricted Stock Units |
| Seshu Tyagarajan Officer | Jun 29, 2026 | 7,000 | $68.53K | Jun 29, 2026 | Restricted Stock Units |
| William Garrett Nichols Officer | Jun 30, 2025 | 3,593 | $17.61K | Jun 30, 2025 | Exercise of Stock Options |
| Paul Peter Tak Director, Officer | Mar 18, 2025 | 74,106 | $654.36K | Mar 18, 2025 | Open Market Purchase |
| Francesca Barone Officer | Mar 18, 2025 | 32,146 | $283.85K | Mar 18, 2025 | Exercise of Stock Options |
| William Garrett Nichols Officer | Mar 18, 2025 | 45,316 | $400.14K | Mar 18, 2025 | Exercise of Stock Options |
| Seshu Tyagarajan Officer | Mar 17, 2025 | 31,278 | $273.68K | Mar 17, 2025 | Exercise of Stock Options |
| Charles Schoch Officer | Mar 17, 2025 | 5,000 | $43.75K | Mar 17, 2025 | Open Market Purchase |
| Paul Peter Tak Officer, Director | Jan 15, 2025 | 19,970 | $156.56K | Jan 15, 2025 | RSU Award |
| Charles Schoch Officer | Jan 15, 2025 | 8,751 | $68.61K | Jan 15, 2025 | RSU Award |
| Francesca Barone Officer | Jan 15, 2025 | 12,452 | $97.62K | Jan 15, 2025 | RSU Award |
| Seshu Tyagarajan Officer | Jan 15, 2025 | 13,177 | $103.31K | Jan 15, 2025 | RSU Award |
| William Garrett Nichols Officer | Jan 15, 2025 | 9,564 | $75.22K | Jan 15, 2025 | RSU Award |
See a number that looks wrong?